Successful treatment of refractory cutaneous leishmaniasis with GM-CSF and antimonials

American Journal of Tropical Medicine and Hygiene

Volumn 73, Issue 1, 2005, Pages 79-81

  Almeida, Roque P ^a   Brito, Jussamara ^a   Machado, Paulo L ^a   De Jesus, Amélia R ^a   Schriefer, Albert ^a   Guimarães, Luiz Henrique ^a   Carvalho, Edgar M ^a  

^a FEDERAL UNIVERSITY OF BAHIA   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

MEGLUMINE ANTIMONATE; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

ADOLESCENT; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DISEASE DURATION; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HUMAN; LEISHMANIA BRAZILIENSIS; LEISHMANIASIS; MALE; OPEN STUDY; SKIN LEISHMANIASIS; SKIN ULCER; TREATMENT OUTCOME; ULCER HEALING;

LEISHMANIA BRAZILIENSIS;

EID: 24644433833     PISSN: 00029637     EISSN: None     Source Type: Journal    
DOI: 10.4269/ajtmh.2005.73.79     Document Type: Article

References (22)

1. Modabber F, 1987. The Leishmaniases. Maurice J, Pearce AM, eds. Tropical Diseases Research: A Global Partnership. Eight Programme Report. Geneva: World Health Organization, 99-112.
2. Bittencourt AL, Barral-Netto M, 1995. Leishmaniasis. Doerr W, Seifert G, eds. Tropical Pathology. Heidelberg: Springer, 597-651.
3. Berman JD, 1997. Human leishmaniasis: clinical, diagnostic and chemotherapeutic development in the last 10 years. Clin Infect Dis Apr 24: 684-703.
4. Barral-Netto M, Machado P, Bittencourt AL, Barral A, 1997. Recent advances in the pathophisiology and treatment of human cutaneous leishmaniasis. Curr Opin Dermatol 4: 51-58.
5. Sampaio SA, Castro RM, Dilon NL, Martins JE, 1971. Treatment of mucocutaneous (American) leishmaniasis with amphetericin B: report of 70 cases. Int J Dermatol 10: 179-181.
6. Soto-Mancipe J, Grogl M, Berman JD, 1993. Evaluation of pentamidine for the treatment of cutaneous leishmaniasis in Colombia. Clin Infect Dis 16: 417-425.
7. Koff AB, Rosen T, 1994. Treatment of cutaneous leishmaniasis. J Am Acad Dermatol 31: 693-708.
8. Lieschke GL, Burgess AW, 1992. Granulocyte colony-stimulating factor and granulocyte-macrophage-colony stimulating factor. N Engl J Med 327: 99-106.
9. Jones TC, 1996. The effect of granulocyte-macrophage colony-stimulating factor (rhGM-CSF) on macrophage function in microbial disease. Med Oncol 13: 141-147.
10. Ho JL, Reed SG, Wick EA, Giordano M, 1990. Granulocyte-macrophage and macrophage colony stimulating factors activate intramacrophage killing of Leishmania mexicana amazonensis. J Infect Dis 162: 224-230.
11. Al-Zamel F, Al-Shammary FJ, El-Shewemi S, 1996. Enhancement of leishmanicidal activity of human macrophages against Leishmania major and Leishmania donovani infection using recombinant human granulocyte-macrophage colony-stimulating factor. Zentralbl Bakteriol. 285: 92-105.
12. Jones TC, 1993. The effects of rhGM-CSF on macrophage function. Eur J Cancer 29 (Suppl 3): 10-13.
13. Marques da Costa R, Aniceto C, Jesus FM, Mendes M, 1994. Quick healing of leg ulcers after molgramostim. Lancet 344: 481-482.
14. Kurzrock R, Talpaz M, Gutterman JU, 1992. Very low doses of GM-CSF administered alone or with erythropoietin in aplastic anemia. Am J Med 93: 41-48.
15. Jaschke E, Zabernigg A, Gattinger C, 1999. Recombinant human granulocyte-macrophage colony-stimulating factor applied locally in low doses enhances healing and prevents recurrence of chronic venous ulcers. Int J Dermatol 38: 380-386.
16. Robson MC, Phillips TJ, Falanga V, Odenheimer DJ, Parish LC, Jensen JL, Steed DL, 2001. Randomized trial of topically applied repifermin (recombinant human keratinocyte growth factor-2) to accelerate wound healing in venous ulcers. Wound Repair Regen 9: 347-352.
17. Almeida RP, D'Oliveira A Jr, Machado P, Bacellar O, Ko AI, Ribeiro de Jesus A, Mobashery N, Santos JB, Carvalho EM, 1999. Randomized, double-blind study of stibogluconate plus human granulocyte macrophage colony-stimulating factor versus stibogluconate alone in the treatment of cutaneous leishmaniasis. J Infect Dis 180: 1735-1737.
18. Santos JB, de Jesus AR, Machado PR, Magalhães A, Salgado S, Carvalho EM, Almeida RP, 2004. Recombinant human GM-CSF applied topically in low doses plus antimony enhances healing of cutaneous leishmaniasis ulcers: a randomized, double-blind study. J Infect Dis 190: 1793-1796.
19. Robson M, Kucukcelebi A, Carp SS, 1994. Effects of granulocyte-macrophage colony-stimulating factor on wound contraction. Eur J Clin Microbiol Infect Dis 13: 41-46.
20. Kaplan G, Walsch G, Guido LS, Meyn P, Burkhardt RA, Abalos RM, Barker J, Frindt PA, Fajardo TT, Celona R, 1992. Novel responses of human skin to intradermal recombinant granulocyte/macrophage-colony-stimulating factor. Langerhans cell recruitment, keratinocyte growth, and enhanced wound healing. J Exp Med 175: 1717-1728.
21. Kucukcelebi A, Carp SS, Haward PG, 1992. Granulocyte-macrophage colony-stimulating factor reverses the inhibition of wound contraction caused by bacterial contamination. Wounds 4: 241-247.
22. Doherty TM, Coffman RL, 1993. Leishmania antigens presented by GM-CSF-derived macrophages protect susceptible mice against challenge with Leishmania major. J Immunol 150: 5476-5483.